Home \ Antibodies \ C5aR, Rat, mAb R63
Catalog # HM3017

C5aR, Rat, mAb R63

The monoclonal antibody R63 reacts with the rat receptor for C5a (CD88).

Read more
Please choose the quantity of items you wish to add to your cart…
Find distributor

The monoclonal antibody R63 reacts with the rat receptor for C5a (CD88).

The rat anaphylatoxin C5a, a 77-amino acid glycopolypeptide generated by proteolytic cleavage of C5, is one of the most potent inflammatory chemo attractants and interacts with two C5a receptors, C5aR and C5L2.- Most of the C5a effects are mediated through C5aR. C5aR is known to be crucial in the initiation of acute inflammatory responses.

C5a receptor is a seven transmembrane GTP-binding-protein-coupled receptor that belongs to the rhodopsin supergene family. The 45 kDa C5a receptor is expressed by leukocytes such as neutrophils, eosinophils, basophils, monocytes, dendritic cells and mast cells. C5aR can be expressed on both immune and non-immune cells.

The latter, include vascular endothelial cells, cardiomyocytes and bronchial epithelial cells. Signaling of C5aR involves intracellular calcium mobilization and activation of among others protein kinase- B (PKB) and protein phospholipase D (PLD) pathways. High C5aR expression levels have been associated with the pathogenesis of many inflammatory conditions, autoimmune and neurodegenerative diseases like rheumatoid arthritis, multiple sclerosis, atherosclerosis and inflammatory bowel disease. In vivo blockade of C5aR greatly reduces inflammatory injury.

Using immunohistology there is no evidence for non-myeloid expression in healthy control rats. However, under inflammatory situations, the C5aR was found to be upregulated in various organs and tissues including the liver.Antibody
R63 is directed against the amino-terminal domain Ex1 of the rat C5aR.

Flow cytometry, Frozen sections, Immuno assays, Immuno fluorescence, Western blot

Application Notes
IHC-F: 7 µm frozen paraformaldehyde fixed sections were blocked with serum and incubated with mAb at 5  µg/ml
FC: 2x105 cells were incubated with mAb at 3-5  µg/ml, all incubations on ice
W: cell homogenate was separated on 10% SDS-PAGE and blotted on nitrocellulose. After blocking blot was incubated with mAb (1/500-1000)

For immunohistochemistry, flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Product type
Monoclonal antibodies
100 µg, 20 µg
0.2 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide.
RBH-2H3 cells transfected with rat C5aR gene
Mouse IgG1
C5aR; CD88; C5a anaphylatoxin chemotactic receptor; C5a anaphylatoxin receptor; C5a ligand; C5a-R; complement component 5a receptor 1
Storage and stability
Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Infectious diseases, Nephrology

Calculate your ELISA data easily

With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.

Latest Hycult Biotech news

  • New Human Complement Pathway Assays
    We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
  • Navigating the pitfalls in complement analysis
    Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
  • NEW Human C3d ELISA
    We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA
Contact us